Adenosine Or Derivative Patents (Class 514/46)
-
Patent number: 6987095Abstract: The present invention provides for the improved uptake of feed additives, pigments for use in coloring the flesh and the like. This improved intestinal uptake of foodstuffs and additives is effected through enhancing the development of the intestinal tract. Specifically the present method comprises of feeding fish with a diet which has an augmented level of nucleotides present therein. The nucleotides may be selected from the group consisting of nucleotides of uridine, guanosine, cytidine, thymindine, adenosine and mixtures thereof. The resultant improvement in the development of the intestinal tract leads to an improvement of the intestinal surfaces to absorb nutrients and/or dietary additives, this increase being at least partly due to an increase in gut surface area, for example through an increase in villus height.Type: GrantFiled: October 11, 2000Date of Patent: January 17, 2006Assignee: Ewos LimitedInventors: Charles Burrells, Paul David Williams
-
Patent number: 6979468Abstract: A method and composition for the treatment of acne vulgaris, acne rosacea, and other inflammatory skin conditions comprises the oral administration of a composition comprising a dose of nicotinamide delivered at levels substantially in excess of normal dietary levels, the nicotinamide being delivered in combination with zinc. The composition may also include quantities of copper and folic acid. In a most preferred embodiment, the nicotinamide and copper each are present in immediate release formats, while the zinc is present in a sustained release format.Type: GrantFiled: December 6, 2002Date of Patent: December 27, 2005Assignee: Sirius LaboratoriesInventor: Frank Pollard
-
Patent number: 6974803Abstract: The present invention relates to a combination comprising (a) an adenosine A2a receptor agonist as defined herein and (b) an adrenergic ?2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.Type: GrantFiled: December 2, 2002Date of Patent: December 13, 2005Assignee: Pfizer IncInventor: Michael Yeadon
-
Patent number: 6960569Abstract: Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the inevntion include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: GrantFiled: August 15, 2001Date of Patent: November 1, 2005Assignee: TRIPEP ABInventor: Matti Sällberg
-
Patent number: 6949521Abstract: Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vivo to the corresponding drugs, increasing the half-life of the drugs. In addition azide prodrugs are often better able to penetrate the blood-brain barrier than the corresponding drugs. Especially useful are azide derivatives of cordycepin, 2?-F-ara-ddI, AraA, acyclovir, penciclovir and related drugs. Useful azide prodrugs are azide derivatives of therapeutic alicyclic amines, ketones, and hydroxy-substituted compounds, including aralkyl, heterocyclic aralkyl, and cyclic aliphatic compounds, where the amine or oxygen moiety is on the ring, or where the amine or oxygen moiety is on an aliphatic side chain, as well as therapeutic purines and pyrimidines, nucleoside analogs and phosphorylated nucleoside analogs.Type: GrantFiled: May 4, 2001Date of Patent: September 27, 2005Assignees: The University of Georgia Research Foundation, Inc., Emory UniversityInventors: Chung K. Chu, Lakshmi P. Kotra, Konstantine Manouilov, Jinfa Du, Raymond Schinazi
-
Patent number: 6949522Abstract: The present invention includes compounds and compositions of ?-halonucleosides, as well as methods to treat HIV, HBV or abnormal cellular proliferation comprising administering said compounds or compositions.Type: GrantFiled: June 24, 2002Date of Patent: September 27, 2005Assignees: Pharmasset, Inc., The University of Georgia Research Foundation, Inc., Emory UniversityInventors: Michael J. Otto, Junxing Shi, Chung K. Chu, Raymond F. Schinazi, Giuseppe Gumina, Youhoon Chong, Yongseok Choi
-
Patent number: 6946449Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: GrantFiled: July 11, 2002Date of Patent: September 20, 2005Assignee: CV Therapeutics, Inc.Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
-
Patent number: 6936596Abstract: 2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5?-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.Type: GrantFiled: September 7, 2001Date of Patent: August 30, 2005Assignees: Toa Eiyo Ltd., Yamasa CorporationInventors: Takashi Konno, Kazuhiro Uemoto, Shinya Onuma, Yoshikazu Kato
-
Patent number: 6936435Abstract: The production of a purified extracellular bacterial signal called autoinducer-2 is regulated by changes in environmental conditions associated with a shift from a free-living existence to a colonizing or pathogenic existence in a host organism. Autoinducer-2 stimulates LuxQ luminescence genes, and is believed also to stimulate a variety of pathogenesis related genes in the bacterial species that produce it. A new class of bacterial genes is involved in the biosynthesis of autoinducer-2.Type: GrantFiled: September 21, 2001Date of Patent: August 30, 2005Assignees: Princeton University, University Technologies Internat.Inventors: Bonnie L. Bassler, Michael G. Surette
-
Patent number: 6926911Abstract: Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.Type: GrantFiled: December 21, 1999Date of Patent: August 9, 2005Assignee: The University of North Carolina at Chapel HillInventor: Richard C. Boucher, Jr.
-
Patent number: 6921753Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.Type: GrantFiled: June 19, 2001Date of Patent: July 26, 2005Assignee: Pfizer IncInventors: Simon John Mantell, Sandra Marina Monaghan, Peter Thomas Stephenson
-
Patent number: 6921754Abstract: Compositions are proposed which comprise folic acid in combination with 5-methyltetrahydrofolic acid, and also compositions which comprise folic acid, 5-methyltetrahydrofolic acid and/or 5-methyltetrahydrofolylpolyglutamate and also comprise a dietary component and/or a nutrient preparation, and their use is also proposed.Type: GrantFiled: May 3, 2001Date of Patent: July 26, 2005Assignee: BASF AktiengesellschaftInventors: Wolfgang Hähnlein, Klaus Krämer, Oliver Hasselwander, Loni Schweikert
-
Patent number: 6919320Abstract: The invention relates to compositions comprising 2?-deoxyribonucleosides. The invention also relates to methods of accelerating the healing of wounds, abrasions, cuts, incisions, and superficial burns induced by heat, sunlight, chemical agents, or infections, and methods for ameliorating the effects of aging of the epidermal tissues comprising administering the compositions of the present invention to an animal.Type: GrantFiled: June 7, 1995Date of Patent: July 19, 2005Assignee: Wellstat Therapeutics CorporationInventors: Reid Warren von Borstel, Michael Kevin Bamat
-
Patent number: 6914053Abstract: Disclosed are novel adenosine A3 receptor agonists of Formula I: wherein: R is hydrogen or lower alkyl; R1 is optionally substituted lower alkoxy or optionally substituted cycloalkyloxy; R2 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted trialkylsilyl; and R3 is hydroxymethyl or R4R5NC(Q)—; in which R4 and R5 are hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.Type: GrantFiled: September 8, 2003Date of Patent: July 5, 2005Assignee: CV Therapeutics, Inc.Inventor: Gloria Cristalli
-
Patent number: 6911435Abstract: Adenosine and active agent which interact with the adenosine system are used to treat conditions of weakened, immune system, as an anti-cancer therapy and for improving the therapeutic index of a variety of therapeutic drugs.Type: GrantFiled: July 10, 1998Date of Patent: June 28, 2005Assignee: Can-Fite Biopharma Ltd.Inventors: Ilan Cohn, Pnina Fishman
-
Patent number: 6903079Abstract: The invention provides a novel class of substituted nucleoside derivatives having the formula: A-Z1-L-Z2-G wherein: A and G are connected via Z1 and Z2 respectively, to a linker, L; and A is: wherein: X1 and X2 are N; X3 is —N?CH; R1 and R2 are independently H, alkyl, NH2, OH, SH, Cl, NHR9, or N?NR9, where R9 is alkyl, aryl, or arylalkyl; R5 and R6 are independently alkyl, or R5 and R6 taken together form a —C(CH3)2— group; Z1 is —CH2O—, —CH2NR10—, —CH2NR10C(O)—, —CONR10—, —CO2—, —CH2NHCONH—, —CH2—, —CH2NHCSNH—, —CO—, —CH2CO2—, —NHCO2—, —S—, —SO2—, —CH2S—, or —SO—; Z2 is —NR10CO—, —C(O)NR10—, —NHCONH—, —OC(O)—, —C(O)O—, NHCS, —CSNH—, —NHCSNH—, —O—, —CO—, —OCO—, —OCONH—, —NH—, —CH2—, —CH—alkyl—, —NHCO2—, —S—, —SO2—, CS—, or —SO—; L is H, O, S, C1-15 alkylene chain optionally substituted in one or more positions, a 5, 6 or 7 membered carbocycle, piperidine, piperazine, pyrole, imidazole, benzimidazole, tetrazoles, indole, isoquinoline, quinoline, or pyrrolidine, any of the 5, 6 or 7 membered carbocyclType: GrantFiled: December 16, 2002Date of Patent: June 7, 2005Assignee: Inotek Pharmaceuticals CorporationInventors: Prakash Jagtap, Garry Southan, Andrew Salzman, Csaba Szabo, Siya Ram
-
Patent number: 6900182Abstract: Compositions comprising inositolphosphoglycans (IPGs) and ribose are disclosed, and their use in the prevention or treatment of ischaemic-reperfusion injury. This treatment increases the energy generating systems of cells by employing the mitochondrial oxidative restoration system. The use of the compositions in preserving organs for transplantation is also disclosed.Type: GrantFiled: May 12, 1999Date of Patent: May 31, 2005Assignee: Sylus Pharmaceuticals Ltd.Inventors: Thomas William Rademacher, Leslie Greenbaum, Patricia McLean
-
Patent number: 6900309Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds as adenosine A2a receptor agonists.Type: GrantFiled: June 8, 2000Date of Patent: May 31, 2005Assignee: Pfizer IncInventors: Simon J. Mantell, Sandra M. Monaghan
-
Patent number: 6881831Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.Type: GrantFiled: May 15, 2002Date of Patent: April 19, 2005Assignee: Migenix Inc.Inventors: Radhakrishnan P. Iyer, Yi Jin, Arlene Roland, Wenqiang Zhou
-
Patent number: 6875750Abstract: Aziridine derivatives of formula (I) are disclosed which can be used as cofactor for S-adenosyl-L-methionine-dependent methyltransferases.Type: GrantFiled: July 28, 1999Date of Patent: April 5, 2005Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.Inventors: Marc Pignot, Elmar Weinhold
-
Patent number: 6863906Abstract: This invention provides therapeutic compositions and combinations for the protection, treatment and repair of liver tissue. The invention relates to novel compositions and combinations comprising two or more compounds selected from the group consisting of S-adenosylmethionine, L-ergothioneine, and a substance selected from the group consisting of constituents of Milk thistle (Silybum marianum), silymarin and active components of silymarin, whether naturally, synthetically, or semi-synthetically derived, and to methods of preventing and treating liver disease and of repairing damaged liver tissue. The invention also provides a method of administering these compositions and combinations to humans or animals in need thereof.Type: GrantFiled: May 24, 2002Date of Patent: March 8, 2005Assignee: Nutramax Laboratories, Inc.Inventors: Todd R. Henderson, Barbara E. Corson
-
Patent number: 6858590Abstract: Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.Type: GrantFiled: August 15, 2001Date of Patent: February 22, 2005Assignee: TRIPEP ABInventors: Matti Sällberg, Catharina Hultgren
-
Publication number: 20040266722Abstract: The present invention relates to the use of nucleoside derivatives of formula I 1Type: ApplicationFiled: July 15, 2004Publication date: December 30, 2004Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20040259832Abstract: Composition and methods are disclosed that include a synergistic combination of an inhibitor of Herpes simplex virus thymidine kinase, and an antiherpes substance.Type: ApplicationFiled: January 29, 2004Publication date: December 23, 2004Inventor: George E. Wright
-
Publication number: 20040259833Abstract: This invention provides broad-spectrum antibiotics that are inhibitors of bacterial adenine DNA methyltransferases.Type: ApplicationFiled: June 25, 2004Publication date: December 23, 2004Applicants: The Board of Trustees of the Leland Stanford Junior University, The Penn State Research FoundationInventors: Stephen J. Benkovic, Lucille Shapiro, Stephen J. Baker, Daphne C. Wahnon, Mark Wall
-
Patent number: 6833361Abstract: Conformationally restricted 2′, 4′-bridged nucleoside analogues are described herein. The compounds can be prepared by cyclization at C2′ and C4′ of nucleosides through a linker or linking molecule. These novel nucleosides have a desired, locked sugar pucker and are potentially useful as pharmaceutical ingredients, and especially for use in treatment of HCV.Type: GrantFiled: April 30, 2002Date of Patent: December 21, 2004Assignee: Ribapharm, Inc.Inventors: Zhi Hong, Haoyun An
-
Patent number: 6833362Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: June 7, 2001Date of Patent: December 21, 2004Inventors: Ward Beryl Bowen, Jr., Daniel Salman Daniel
-
Publication number: 20040254095Abstract: The ingestible supplement for treating muskuloskeletal disorders is made of per supplement from about 250 mg to about 2500 mg of 2-amino-2-deoxyglucose sulfate, 2-amino-2-deoxyglucose sulfate hydrochloride, n-acetyl 2-amino-2-deoxyglucose sulfate, or combinations thereof; from about 40 mg to about 750 mg of acetyl myristoleate; from about 40 mg to about 800 mg of s-adenosylmethionine; from about 200 mg to about 2000 mg of a protein; from about 100 mg to about 2500 mg of Vitamin B, Vitamin C, Vitamin E, or complexes thereof; and from about 1000 mg to about 9000 mg of a fiber. A method for improving joint mobility in a subject comprising administering to the subject an amount of the supplement involves administering to a subject an amount of the supplement on a regular basis.Type: ApplicationFiled: December 2, 2003Publication date: December 16, 2004Inventors: Kenneth A. Martin, Teresa Leigh Barr
-
Publication number: 20040254094Abstract: The present invention relates to methods for use in treating or preventing infections. More particularly, the invention relates to methods for screening for modulators that inhibit cyclin-dependent kinase and the use of these putative inhibitors to control proliferation of a DNA virus that is dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly human cytomegalovirus.Type: ApplicationFiled: October 10, 2001Publication date: December 16, 2004Applicants: The Trustees of University of Pennsylvania and Board of Regents, The University of Texas SystemInventors: Thomas Albrecht, Laurent Meijer, Priscilla Schaffer, Luis Schang
-
Patent number: 6831072Abstract: The present invention is directed to a method to produce 8-amino-2′deoxyadenosine by treating 8-azido-2′deoxyadenosine with an aqueous solution of methylamine or dimethylamine.Type: GrantFiled: January 22, 2002Date of Patent: December 14, 2004Assignee: Cygene, Inc.Inventors: Ramón Eritja, Ramón Güimil García
-
Publication number: 20040248843Abstract: There is described a process for the preparation of tablets comprising S-adenosylmethionine which comprises blending S-adenosylmethionine with calcium sulfate and/or phosphate, calcium and/or magnesium carbonate, glycerol behenate and or palmtostearate and silica and compressing the resulting mixture. The tablets obtainable by the process of the invention are stable and show a low relative humidity and hygroscopicity.Type: ApplicationFiled: April 1, 2004Publication date: December 9, 2004Inventor: Giuseppe Cianfarani
-
Publication number: 20040241256Abstract: The compositions of this invention comprise a mixture of (1) phenylalanine and a dietary food supplement, (2) leucine and a dietary food supplement, and (3) hydrocinnamic acid and a dietary food supplement. The compositions are used for medicinal purposes to alleviate a variety of maladies.Type: ApplicationFiled: June 3, 2004Publication date: December 2, 2004Inventors: Seymour Ehrenpreis, Lawrence Howard
-
Publication number: 20040242904Abstract: A novel sordarin derivative was isolated from fungal cultures. The compound is useful in the treatment and/or prevention of human and animal fungal infections, as well as in the control of phytopathogenic fungi in crops. Two novel cultures of fungi, ATCC No. PTA-3862 and ATCC No. PTA-3861 can be used to ferment and produce the present compound.Type: ApplicationFiled: June 3, 2004Publication date: December 2, 2004Inventors: Angelo Basilio, Javier Collado, Maria Teresa Diez, Ziqiang Guan, Guy H Harris, Michael C Justice, Jennifer Nielsen-Kahn, Mythili S Shastry
-
Publication number: 20040242531Abstract: The present invention discloses a method for treating heart rhythm disturbances in a mammal in need thereof by the administration of N6-substituted-5′-(N-substituted)carboxamidoadenosines.Type: ApplicationFiled: June 29, 2004Publication date: December 2, 2004Applicant: Aderis Pharmaceuticals, Inc.Inventor: Pauline L. Martin
-
Publication number: 20040235781Abstract: In accordance with the present invention there is provided a pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising a compound of the formula (I) 1Type: ApplicationFiled: March 25, 2004Publication date: November 25, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Heinz-Gerd Klaes, Elena Koundourakis, Hernan Valdez, Douglas Lytle Mayers
-
Publication number: 20040235779Abstract: In accordance with the present invention there is provided a pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising tipranavir and at least one antiviral active compound of formula (I) 1Type: ApplicationFiled: March 25, 2004Publication date: November 25, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Heinz-Gerd Klaes, Elena Koundourakis, Hernan Valdez, Douglas Lytle Mayers
-
Publication number: 20040235783Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.Type: ApplicationFiled: June 29, 2004Publication date: November 25, 2004Inventors: Miklos Ghyczy, Jorg Hager, Armin Wendel
-
Publication number: 20040235780Abstract: In accordance with the present invention there is provided a pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising nevirapine and at least one antiviral active compound of formula (I) 1Type: ApplicationFiled: March 25, 2004Publication date: November 25, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Heinz-Gerd Klaes, Elena Koundourakis, Hernan Valdez, Douglas Lytle Mayers
-
Publication number: 20040229837Abstract: A method of increasing the number of activated astrocytes in a subject. The method involves identifying a subject suffering from or being at risk for developing a neurodegenerative disease and administering to the subject an effective amount of an agonist of the A2A-adenosine receptor. Also disclosed are a method of treating a neurodegenerative disease, a packaged product for treating a subject suffering from or being at risk for developing a neurodegenerative disease, and a method of identifying an agonist of the A2A-adenosine receptor for treating a neurodegenerative disease.Type: ApplicationFiled: May 15, 2003Publication date: November 18, 2004Inventors: Yijuang Chern, Yi-Chao Lee
-
Publication number: 20040229838Abstract: The present invention relates to compounds of the formula 1Type: ApplicationFiled: June 15, 2004Publication date: November 18, 2004Applicant: Pfizer IncInventors: Simon John Mantell, Sandra Marina Monaghan, Peter Thomas Stephenson
-
Publication number: 20040204375Abstract: Compounds having the structure: 1Type: ApplicationFiled: November 3, 2003Publication date: October 14, 2004Inventors: Eric J Sorscher, Jeong S Hong, Jennifer E Harris, Kimberly V Curlee, Joseph A Maddry, William B Parker, William R Wand
-
Patent number: 6803457Abstract: A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.Type: GrantFiled: August 17, 2000Date of Patent: October 12, 2004Assignee: Pfizer, Inc.Inventors: Michael P. DeNinno, Hiroko Masamune, Robert W. Scott
-
Publication number: 20040198691Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: ApplicationFiled: February 2, 2004Publication date: October 7, 2004Inventors: Gloria Cristalli, Venkata Palle, Jeff Zablocki
-
Publication number: 20040198693Abstract: A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.Type: ApplicationFiled: April 12, 2004Publication date: October 7, 2004Inventors: Michael P. DeNinno, Hiroko Masamune, Robert W. Scott
-
Publication number: 20040198692Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: ApplicationFiled: March 30, 2004Publication date: October 7, 2004Applicant: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
-
Patent number: 6800616Abstract: Disclosed is a method of treating an HIV-infected host including administering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of treating an HIV-infected host including administering highly active antiretroviral therapy; and coadministering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount.Type: GrantFiled: February 26, 1998Date of Patent: October 5, 2004Assignee: SuperGen, Inc.Inventor: Simeon M. Wrenn, Jr.
-
Publication number: 20040192635Abstract: The invention relates to compositions comprising acyl derivatives of 2′-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced cellular damage, methods for improving wound healing and tissue repair, and methods for ameliorating the effects of aging comprising administering the compositions of the present invention to an animal.Type: ApplicationFiled: April 15, 2004Publication date: September 30, 2004Applicant: Wellstat Therapeutics CorporationInventors: Reid W. Von Borstel, Michael K. Bamat
-
Publication number: 20040192634Abstract: The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention is also directed to the use of the AT1 receptor or functionally analogous peptides or proteins in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in such biological materials, e.g. in body fluids or tissues.Type: ApplicationFiled: May 24, 2004Publication date: September 30, 2004Inventors: Kai Schulze-Forster, Harald Heidecke
-
Publication number: 20040192553Abstract: The present invention discloses an inosine. L-arginine salt, compositions containing the salt, and methods of using the salt and said compositions for cell activation and/or plant growth promotion. The salt can be stored and transported as a solid and dissolves quickly and efficiently when needed.Type: ApplicationFiled: March 25, 2004Publication date: September 30, 2004Inventors: Masahiko Kurauchi, Yuki Miyazawa, Hiroyuki Sato
-
Patent number: 6790837Abstract: A liquid formulation comprising ribavirin having a longer shelf life and improved taste is disclosed.Type: GrantFiled: October 31, 2002Date of Patent: September 14, 2004Assignee: Schering CorporationInventors: Susan K. Heimbecher, Joel A. Sequeira